in vitro transcription for advancing RNA medicine

Codex® HiCap RNA Polymerase is a co-transcriptional capping RNA polymerase engineered to produce synthetic RNA to meet increasing demands for safety and cost-effectiveness. The HiCap enzyme generates fewer undesirable double-stranded RNA (dsRNA) byproducts than wild-type T7 (WT T7) RNA polymerase, reducing unwanted immunogenicity, while efficiently incorporating commercially available cap analogs.

dsRNA byproducts

Figure 1. Significantly reduced dsRNA byproducts by Codex® HiCap RNA Polymerase. mRNAs were transcribed using either WT T7 or Codex® HiCap RNA Polymerase. After IVT was completed, total dsRNA content was quantified via sandwich ELISA using the J2 dsRNA antibody.

Download our brochure for more performance data.

Codex^® HiCap RNA Polymerase vs. Wild-type T7

Codex^® HiCap RNA Polymerase Resources

• Codex^® HiCap RNA Polymerase Brochure
• Codex^® HiCap RNA Polymerase in vitro Transcription Procedure
• Codex^® HiCap RNA Polymerase Guide: Maximizing mRNA Titers
• Poster: HiCap T7 transcribes RNA with higher purity and activity while using less cap analog
• Research Article: An Engineered T7 RNA Polymerase for efficient co-transcriptional capping with reduced dsRNA byproducts in mRNA synthesis
• Press Release: Codexis and Aldevron Enter Exclusive Licensing Agreement for Codex® HiCap RNA Polymerase

Ordering Information

*Codex® is a trademark of Codexis, Inc. Any other third-party trademarks are the property of their respective owners.